VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution

Cardiovascular Research

Volumn 94, Issue 1, 2012, Pages 125-135

  Alexander, Revu Ann ^a   Prager, Gerald W ^a   Mihaly Bison, Judit ^a   Uhrin, Pavel ^a   Sunzenauer, Stefan ^b   Binder, Bernd R ^a   Schütz, Gerhard J ^b   Freissmuth, Michael ^a   Breuss, Johannes M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

Author keywords

Endothelium; Integrin; Internalization; uPAR; VEGF

Indexed keywords

BETA1 INTEGRIN; CLATHRIN; LOW DENSITY LIPOPROTEIN RECEPTOR; UROKINASE RECEPTOR; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; ENDOCYTOSIS; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CLATHRIN-COATED VESICLES; ENDOCYTOSIS; ENDOTHELIAL CELLS; FLOW CYTOMETRY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA5BETA1; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN TRANSPORT; RECEPTORS, LDL; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859075784     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs017     Document Type: Article

References (24)

1. Folkman J. Proceedings: tumor angiogenesis factor. Cancer Res 1974;34:2109-2113.
2. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
3. Koolwijk P, Sidenius N, Peters E, Sier CF, Hanemaaijer R, Blasi F et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 2001;97:3123-3131.
4. Prager GW, Mihaly J, Brunner PM, Koshelnick Y, Hoyer-Hansen G, Binder BR. Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood 2009;113:1383-1390.
5. Brunner PM, Heier PC, Mihaly-Bison J, Priglinger U, Binder BR, Prager GW. Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells. Blood 2011;117:4154-4161.
6. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004;103:955-962.
7. Prager GW, Breuss JM, Steurer S, Olcaydu D, Mihaly J, Brunner PM et al. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res 2004;94:1562-1570.
8. Tanjore H, Zeisberg EM, Gerami-Naini B, Kalluri R. Beta1 integrin expression on endothelial cells is required for angiogenesis but not for vasculogenesis. Dev Dyn 2008;237:75-82.
9. Bohuslav J, Horejsi V, Hansmann C, Stöckl J, Weidle UH, Majdic O et al. Urokinase plasminogen activator receptor, b2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 1995;181:1381-1390.
10. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-1555.
11. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269:32380-32388.
12. Schwarzenbacher M, Kaltenbrunner M, Brameshuber M, Hesch C, Paster W, Weghuber J et al. Micropatterning for quantitative analysis of protein-protein interactions in living cells. Nat Methods 2008;5:1053-1060.
13. Mettouchi A, Meneguzzi G. Distinct roles of beta1 integrins during angiogenesis. Eur J Cell Biol 2006;85:243-247.
14. Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell 2001;12:1467-1479.
15. Geetha N, Mihaly J, Stockenhuber A, Blasi F, Uhrin P, Binder BR et al. Signal integration and coincidence detection in the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) cascade: concomitant activation of receptor tyrosine kinases and of LRP-1 leads to sustained ERK phosphorylation via down-regulation of dual specificity phosphatases (DUSP1 AND -6). J Biol Chem 2011;286: 25663-25674.
16. Chaurasia P, Aguirre-Ghiso JA, Liang OD, Gardsvoll H, Ploug M, Ossowski L. A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J Biol Chem 2006;281:14852-14863.
17. Wei Y, Tang CH, Kim Y, Robillard L, Zhang F, Kugler MC et al. Urokinase receptors are required for a5b1 integrin-mediated signaling in tumor cells. J Biol Chem 2007; 282:3929-3939.
18. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89-104.
19. Mould AP, Garratt AN, Askari JA, Akiyama SK, Humphries MJ. Identification of a novel anti-integrin monoclonal antibody that recognises a ligand-induced binding site epitope on the beta 1 subunit. FEBS Lett 1995;363:118-122.
20. Mazzieri R, D'Alessio S, Kenmoe RK, Ossowski L, Blasi F. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol Biol Cell 2006;17:367-378.
21. Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell 2001;12:2975-2986.
22. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE et al. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 2007;5:61.
23. Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT et al. A phase II, single-arm study of the anti-a5b1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 2011;121:273-279.
24. Dewerchin M, Nuffelen AV, Wallays G, Bouche A, Moons L, Carmeliet P et al. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 1996; 97:870-878.